Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This study tests a new drug called SKB264 against standard chemotherapy in 376 adults with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to targeted therapy. The goal is to see if SKB264 alone can better delay cancer…

This early-phase study tests a new drug called A166 in 120 adults with advanced HER2-expressing solid tumors (like breast cancer) that cannot be removed by surgery or have spread. The main goal is to check safety and find the right dose, while also seeing if tumors shrink. Partic…